CS
Champions Oncology, Inc.
CSBR · NASDAQ
$5.10 +2.11% (+$0.11)
1M +3.03%
Market Cap $70.8M
P/E Ratio -
Div. Yield -
ROE 29.56%
Bulios Fair Price
$6.92
35.8% upside
Current Price
$5.1
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CSBR is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
22 /100
Expensive P/S 1.19x
P/B 17.97x
EV/EBITDA 157.41x
Growth
0 /100
Declining Book val. growth 5.29%
Rev. growth N/A
FCF growth N/A
Profitability
19 /100
Weak Net margin 1.98%
Op. margin 1.92%
FCF margin 8.47%
Quality
15 /100
Poor ROE 29.56%
ROA 4.35%
Asset turnover 2.20x
Debt
67 /100
Low Current ratio 0.96x
Net debt/EBITDA -0.61x
Debt/Equity 1.17x
Stability
14 /100
Unstable Rev. volatility 60.52%
EPS volatility 146.41%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CSBR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Brainin
Employees
214
Headquarters
Hackensack